How Celgene Hopes to Cash In on CAR-T – Motley Fool
|
How Celgene Hopes to Cash In on CAR–T
Motley Fool Chimeric antigen T–cell therapy (CAR-T) is an important new approach to battling blood cancer, and while it’s too soon to say what company will develop an approved treatment first, Celgene (NASDAQ:CELG) has a good shot at coming out on top. In January … |
Salt Lake Tribune |
This Salt Lake City startup says its stem cell treatment will regenerate skin; a New Orleans doctor says it’s …
Salt Lake Tribune The blast of gas and steam burned through Leonard Tayon’s coveralls and skin, down to his muscles and tendons. The liners in his hard hat melted into his head. His rubber gloves melted onto his hands. Skin grafts saved his life after the accident at U … |
Infosurhoy |
Researchers advance CRISPR-based diagnostic tool, develop miniature paper test
Infosurhoy At the core of SHERLOCK’s success is a CRISPR-associated protein called Cas13, which can be programmed to bind to a specific piece of RNA. Cas13’s target can be any genetic sequence, including viral genomes, genes that confer antibiotic resistance in … |